Skip to main content
Sensorion logo

Sensorion — Investor Relations & Filings

Ticker · ALSEN ISIN · FR0012596468 LEI · 969500P0W8XJ9CGZDP97 PA Professional, scientific and technical activities
Open in API
Filings indexed 560 across all filing types
Latest filing 2026-04-21 AGM Information
Country FR France
Listing PA ALSEN

About Sensorion

https://www.sensorion.com/en/

Sensorion is a clinical-stage biotechnology company specializing in the development of novel therapies for inner ear disorders. The company's mission is to address the significant unmet medical need of hearing loss by creating innovative therapeutic solutions. Its strategy is built on three pillars: restoring hearing through gene therapies for genetic diseases, treating existing hearing disorders with small molecule therapeutics, and preventing non-genetic hearing loss, such as drug-induced ototoxicity. Sensorion utilizes a unique R&D technology platform to advance its understanding of the pathophysiology of inner ear diseases and develop its pipeline of clinical candidates.

Recent filings

Filing Released Lang Actions
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 1% confidence The document is a press release announcing the convocation of Sensorion’s mixed Annual General Meeting on May 11, 2026, and the availability of preparatory materials (brochure de convocation, agenda, draft resolutions, voting forms) for shareholders. This is clearly tied to the AGM and provides access to governing documents for that meeting rather than full financials or results disclosure. It fits the “AGM Information” category (materials shared for an AGM).
2026-04-21 French
Terms of availability of the preparatory documents for the GM
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a press release announcing the convening of the Combined Shareholders’ General Meeting, providing the agenda, draft resolutions, details on how to participate and vote (proxy, mail voting), and where to access the preparatory materials. These characteristics match the definition of a Proxy Solicitation & Information Statement (materials sent to shareholders to provide information and request votes for meetings).
2026-04-21 English
Inside Information / Other news releases
Regulatory Filings Classification · 0% confidence The document is a corporate press release providing an operational update on clinical trial progress and future development plans, with no financial result figures or formal investor presentation materials. It does not announce earnings, board changes, dividends, financing, M&A activity, or other specific regulatory disclosures. Therefore it falls into the general regulatory announcement or miscellaneous filings category (RNS).
2026-03-23 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release (“Communiqué de presse”) focusing on clinical trial updates for Sensorion’s gene therapy programs (Audiogene Phase 1/2 data, SENS-601 development timeline, preclinical presentations, etc.). It is not presenting financial results (so it’s not an Earnings Release or Annual/Interim Report), nor is it an investor presentation deck or regulatory notice of a board change or capital transaction. It is a general corporate announcement about clinical progress, which does not fit any of the more specific categories and therefore falls into the fallback “Regulatory Filings” category (RNS).
2026-03-23 French
Inside Information / News release on accounts, results
Report Publication Announcement Classification · 1% confidence The document is a press release from Sensorion reporting its full-year 2025 financial results, providing a corporate update, and announcing the availability of the annual report. While it contains financial highlights and tables, it is structured as a press release (indicated by 'Press Release' headers and contact/date information) rather than the full statutory Annual Report itself. According to the 'Menu vs Meal' rule, this is an announcement of the report's availability, making it a Report Publication Announcement (RPA).
2026-03-18 English
Informations privilégiées / Communiqué sur comptes, résultats
Management Reports Classification · 1% confidence The document is a press release from Sensorion titled 'Sensorion publie ses résultats annuels 2025' (Sensorion publishes its 2025 annual results). It provides a summary of financial highlights, clinical trial updates, management changes, and capital financing. While it mentions the publication of the annual report, the document itself contains the core financial and operational highlights (the 'meal') rather than just being a notification of availability. Given the comprehensive nature of the summary covering financial results, business trends, and outlook, it aligns best with the Management Reports (MDA) category, which captures management's detailed explanation of results and business outlook.
2026-03-18 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.